Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
You've always done all you can for your patients. They trust you to listen to them and take their pain seriously. Now show them the difference
a multimodal postsurgical pain management approach with EXPAREL can make for their recovery goals.
Nurses are the most trusted professionals.
For the past 20 years, nursing has been the top-ranked profession for high honesty and ethics.4†
95% of patients say listening to them is critical5‡
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
†Annual Gallup rating of the honesty and ethics of various professions.
‡Beryl Institute survey of what health care consumers consider to be extremely important to their experience.
Inadequate pain management after surgery can lead to unintended consequences for your patients—from chronic pain to extended hospital stays. In addition, postsurgical pain significantly contributes to patient dissatisfaction with the anesthesia and surgical experience.6
TEAMWORK is key to ERAS pathway success
§Data shown are from colorectal surgery.
LOS, length of stay.
Opioid-related adverse events (ORAEs) can add to your workload. With the growing number of patients you’re caring for, you shouldn’t have to contend with patients who are:
Fortunately, there are non-opioid postsurgical pain management options to help you. If additional pain relief is needed after surgery, patients should receive an around-the-clock regimen of NSAIDs, COX inhibitors, and/or acetaminophen (unless contraindicated).13,14
COX, cyclooxygenase; NSAID, non-steroidal anti-inflammatory drug.
If you are administering pain management medications following surgery, consider the patient types who may react differently to opioids.
For example:
AORN
“When leveraged effectively, multimodal analgesia can be an integral part of improving the surgical patient experience, improving pain control and solving the opioid crisis.”16
AWHONN
“Nurses should be competent in screening approaches to identify the use of legal and illegal substances and SUD in pregnant women and women who may become pregnant.”17
ASPMN
“…prescribing and administering doses of opioid analgesics based solely on a patient’s pain intensity should be prohibited”18
ASPAN
“…opioids now require careful governance and judicious utilization.”19
NAON
“The use of multimodal analgesia and an alternative method of pain control can be highly effective and can decrease burdens of opioid use on patients and their families.”20
AORN, Association of periOperative Registered Nurses; ASPAN, American Society of PeriAnesthesia Nurses; ASPMN, American Society for Pain Management Nursing; AWHONN, Association of Women’s Health, Obstetric, and Neonatal Nurses; NAON, National Association of Orthopaedic Nurses; SUD, substance use disorder.
75% to 88% of patients report moderate to extreme postsurgical pain6
Nearly 80% of patients preferred a non-opioid postsurgical pain management option22
85% of patients were satisfied with EXPAREL
pain control
69% of patients who did not receive EXPAREL
A phase 4, multicenter, double-blind, active-controlled, parallel-group trial in which patients were randomized 1:1 to receive local infiltration analgesia with EXPAREL (n=70) or bupivacaine HCl alone (n=69; P=0.036).
EXPAREL is administered during surgery and works directly at the site to provide targeted analgesia.
Unlike PCA, EXPAREL controls pain while minimizing the need for opioids without pumps or catheters. Less opioid use reduces the risk of opioid-related side effects that can hinder the achievement of key recovery milestones (eg, time to first bowel movement or flatus, eating solid foods, ambulation, and discharge).
With up to 72 hours of pain control, EXPAREL helps patients recover without the side effects of opioids.
§The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
ERAS, enhanced recovery after surgery; LOS, length of stay; PCA, patient-controlled analgesia.
Access the EXPAREL resources that most nurses depend on.
Submission confirmed
Thank you for submitting your query. An EXPAREL clinical educator will contact you in a timely manner.
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.